Labcorp is proud to offer the first available ATN Profile

Our ATN Profile is based on years of research on individual markers that, together, reflect the biological changes consistent with Alzheimer’s disease. 


ATN Profile

This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology

Each of the biomarker tests are orderable individually.

  • 505725

    Beta Amyloid 42/40 Ratio, Plasma

    Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease


    Phosphorylated Tau 181 (pTau-181), Plasma

    This test detects and quantifies pTau181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias


    Neurofilament Light Chain, Plasma

    NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration

Providing clear, objective answers to clinicians, patients and families

Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.

We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.


  1. Alzheimer’s Association.
  2. Anderson LA, Day KL, Beard RL, “The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review”. The Gerontologist. 2009; 49(S1): S3–S11.
  3. Janelidze S, Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 202; 26(3):379-386.
  4. Thijssen EH, Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020; 26(3): 387–397.
  5. Karikair, TK, Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020 May;19(5):422-433.
  6. Cullen, N.C., et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1, 114–123 (2021).
  7. Palmqvist S, Zetterberg H, Mattsson N, “Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.” Neurology. 2015;85:1–10
  8. Hansson O, Seibyl J, Stomrud E, “CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.” Alzheimer’s & Dementia. 2018; 14(11): P1470-1481.

 Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.

Biomarkers for Drug Development

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.